Algernon Pharmaceuticals CEO Christopher J. Moreau at Psychedelic Capital Virtual Investment Conference, Feb 2021 | Microdose


Algernon Pharmaceuticals CEO, Christopher J. Moreau and Scientific Advisor, Dr. David Nutt speak with host Cyndi Edwards about the company’s new DMT Stroke Clinical Research Program.

About Algernon Pharmaceuticals: Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.

Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several potential benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

The Algernon business model is to take safe already approved drugs, including naturally occurring compounds, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then efficiently move them into clinical trials.

Full event recording located at: